239 related articles for article (PubMed ID: 33991528)
21. FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary Tumors.
Kolnes AJ; Øystese KAB; Olarescu NC; Ringstad G; Berg-Johnsen J; Casar-Borota O; Bollerslev J; Jørgensen AP
J Clin Endocrinol Metab; 2020 Aug; 105(8):2587-94. PubMed ID: 32421791
[TBL] [Abstract][Full Text] [Related]
22. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
Nagamine T; Fukuda I
No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
[TBL] [Abstract][Full Text] [Related]
23. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
24. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
25. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
26. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
27. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.
Asa SL; Mete O; Schüller U; Ramani B; Mirchia K; Perry A
Am J Surg Pathol; 2023 Apr; 47(4):469-475. PubMed ID: 36543154
[TBL] [Abstract][Full Text] [Related]
28. Expression of kisspeptin and KISS1 receptor in pituitary neuroendocrine tumours - an immunohistochemical study.
Mihajlovic M; Pekic S; Doknic M; Stojanovic M; Miljic D; Soldatovic I; Vukotic T; Janev T; Cirovic S; Terzic T; Raicevic S; Skender-Gazibara M; Popovic V; Manojlovic-Gacic E
Endokrynol Pol; 2021; 72(2):91-96. PubMed ID: 33619706
[TBL] [Abstract][Full Text] [Related]
29. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB
Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667
[TBL] [Abstract][Full Text] [Related]
30. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
Mete O; Wenig BM
Head Neck Pathol; 2022 Mar; 16(1):123-142. PubMed ID: 35312985
[TBL] [Abstract][Full Text] [Related]
31. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
32. [Acidophil stem cell pituitary neuroendocrine tumors/adenoma: a clinicopathological analysis of five cases].
Lou L; Du SX; Fu YT; Shao QQ; Guo WL; Zong YP; Qin MM; Tian XX; Li YH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):446-451. PubMed ID: 38678324
[No Abstract] [Full Text] [Related]
33. Analysis of Insulinoma-Associated Protein 1 Expression in Pituitary Neuroendocrine Tumors.
Hirokawa Y; Inomoto C; Oyama K; Tahara S; Y Osamura R; Shiomi T; Matsuno A
Acta Histochem Cytochem; 2023 Dec; 56(6):105-110. PubMed ID: 38318099
[TBL] [Abstract][Full Text] [Related]
34. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
35. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
37. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
38. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
39. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
40. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
Asa SL
Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
